Galatea

WEBTOON and Atlantic Records’ Hayley Kiyoko, Ava Max, and MAY-A Partner for “Love Stories,” a New Webcomic Anthology Miniseries Celebrating LGBTQ+ Stories

Retrieved on: 
Thursday, June 1, 2023

WEBTOON , the world’s largest digital comics platform, and Atlantic Records today announced “Love Stories,” a webcomic miniseries celebrating LGBTQ+ stories for Pride Month.

Key Points: 
  • WEBTOON , the world’s largest digital comics platform, and Atlantic Records today announced “Love Stories,” a webcomic miniseries celebrating LGBTQ+ stories for Pride Month.
  • Available exclusively on WEBTOON, the three-episode anthology will explore deeply personal love stories inspired by songs from trailblazing pop star Hayley Kiyoko, global pop sensation Ava Max, and acclaimed pop singer-songwriter MAY-A.
  • View the full release here: https://www.businesswire.com/news/home/20230601005367/en/
    WEBTOON and Atlantic Records today announced “Love Stories,” a webcomic miniseries celebrating LGBTQ+ stories for Pride Month.
  • Johnny Rain),” her episode from WEBTOON creators Color_LES and Galatea, will be available June 12 on WEBTOON, with Ava Max’s episode, “Sleepwalker”, from WEBTOON artist Hannah Pattern launching on June 19.

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

Retrieved on: 
Monday, March 13, 2023

IRVINE, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the full-year ended December 31, 2022, and recent business achievements.

Key Points: 
  • Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA
    IRVINE, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the full-year ended December 31, 2022, and recent business achievements.
  • “In 2022 we had a clear vision to transform eyelid health, starting with the development of our novel investigational treatment for Demodex blepharitis, a disease that impacts millions of Americans.
  • This year, we continue to focus on this unique opportunity, and we are actively educating the market on the disease as we move closer to our PDUFA target action date,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
  • “Alongside our efforts in Demodex blepharitis, we’re working to advance our pipeline, including the initiation of our Phase 2 trial in rosacea, and our planned Phase 2a data readouts from our Lyme disease prevention and MGD-related trials in the second half of 2023.